Oxidized Lipids and UV Immunosuppression
Oxidized Lipids and UV Immunosuppression
批准号:
10010381
负责人:
Jeffrey B. Travers
金额:
$0.0万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-10-01 至 2024-09-30
关键词:
Actinic keratosisAddressAgonistAntioxidantsAreaCarcinogensCell LineCellsChemotherapy and/or radiationCigaretteClinicDataDermatologyDiagnosisDoseEnzyme InhibitionEnzymesEpidermisEpithelial CellsEventFeverFinancial HardshipGenerationsGeneticGoalsGrantHealthcare SystemsHumanImmune responseImmunosuppressionImmunosuppressive AgentsIn VitroIncidenceIndividualIonsKnock-outKnockout MiceKnowledgeLaboratoriesLinkMalignant - descriptorMediatingMembraneMetabolicMilitary PersonnelModelingMorbidity - disease rateMusMutagensNeoplasmsNuclearNull LymphocytesOutcomeOxidesPUVA PhotochemotherapyPathway interactionsPharmacologyPhotobiologyPhotosensitivityPhysiologicalPlatelet Activating FactorPlayProcessProductionRadiation therapyReactionReactive Oxygen SpeciesReceptor SignalingReportingResearchRoleRunningSignal PathwaySignal TransductionSignal Transduction PathwaySkinSkin CancerSkin CarcinomaSkin NeoplasmsSourceStimulusTestingTransfer FactorUV Radiation ExposureUV inducedUV responseUVB inducedUltraviolet B RadiationUltraviolet RaysVesicleVeteransVitamin DWorkXPA geneacid sphingomyelinasedesignenvironmental agentenvironmental stressorgenetic approachin vivoindexinginhibitor/antagonistkeratinocytelipid mediatormast cellmelanomamicrovesiclesmilitary veteranneoplastic cellnoveloxidized lipidparticleplatelet activating factor receptorpremalignantresponsestressortooltumortumor progressionultraviolet
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY
Ultraviolet B (UVB) radiation has profound effects upon skin and generates systemic consequences from fever
to immunosuppression to vitamin D production. The ability of UVB to serve as both an immunosuppressant and
mutagen allows this environmental agent to serve as a complete carcinogen, and is the cause for non-melanoma
skin cancer and melanoma. Skin cancer is the most common diagnosis in VA Dermatology clinics, and this is
expected to increase as our military forces are often stationed in areas with a high UV index. Thus,
understanding the mechanisms by which UVB generates skin cancer is relevant to our veterans. As UVB only
penetrates the epidermis, a major question in photobiology is how UVB-treated skin sends systemic signals.
Recent studies have indicated that small membrane-bound vesicles known as microvesicle particles (MVP)
released from cells in response to various stressors can act as potent signaling agents due to their ability to carry
nuclear and cytoplasmic components. We have demonstrated that UVB generates MVP release from epithelial
cells and skin, which could provide a potential mechanism for UVB-mediated systemic signaling. Our group and
others have previously reported that UVB radiation generates high levels of the lipid mediator Platelet-activating
factor (PAF) produced enzymatically and PAF-receptor (PAFR) agonists produced non-enzymatically via
reactive oxygen species. Recent studies using antioxidants and PAFR-expressing/null cell lines and
pharmacologic/genetic inhibition of the enzyme acid sphingomyelinase (aSMase) have implicated involvement
of PAFR signaling resulting in aSMase activation in UVB generated MVP (UVB-MVP). Finally, we provide
evidence that UVB-MVP carry bioactive PAF agonists, which we hypothesize mediate the delayed
immunosuppressive effects of UVB. Yet knowledge gaps exist as to how UVB-MVP are generated and if this
new pathway can be exploited to address UVB-induced immunosuppression involved in skin tumor
generation/progression. Two aims are planned for the renewal of this long-running and highly productive VA
Merit grant which is centered around the role of oxidized glycerophosphocholines in UV-induced
immunosuppression. These aims are designed to test the hypothesis that UVB generates MVP in human skin in
a PAF-dependent manner involving aSMase and transfers both local and systemic effects via their carried PAF
agonists. Aim 1 will use in vitro cell lines and murine genetic and pharmacologic models to determine the
mechanisms of UVB-MVP generation. Aim 2 will use tools (in part validated in Aim 1) to define the roles of UVB-
MVP in delayed immunosuppressive and tumor-promoting effects of UVB. Successful completion of this project
will (i) address an important question in photobiology as to how a keratinocyte-specific stimulus can generate
systemic signaling effects, (ii) offer pharmacologic mechanisms to block UVB local and systemic effects.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Validation of Mesoscopic Imaging to Predict Cutaneous Carcinogenesis and its Therapeutic Response
-
批准号:10595503
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2019
-
负责人:Jeffrey B. Travers
-
依托单位:
Validation of Mesoscopic Imaging to Predict Cutaneous Carcinogenesis and its Therapeutic Response
-
批准号:10295161
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2019
-
负责人:Jeffrey B. Travers
-
依托单位:
Validation of Mesoscopic Imaging to Predict Cutaneous Carcinogenesis and its Therapeutic Response
-
批准号:10041690
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2019
-
负责人:Jeffrey B. Travers
-
依托单位:
IGF-1 and the initiation of non-melanoma skin cancer
-
批准号:8967172
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2014
-
负责人:Jeffrey B. Travers
-
依托单位:
IGF-1 and the initiation of non-melanoma skin cancer
-
批准号:8539867
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2014
-
负责人:Jeffrey B. Travers
-
依托单位:
IGF-1 and the initiation of non-melanoma skin cancer
-
批准号:8892803
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2014
-
负责人:Jeffrey B. Travers
-
依托单位:
IGF-1 and the initiation of non-melanoma skin cancer
-
批准号:9242476
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2014
-
负责人:Jeffrey B. Travers
-
依托单位:
The Indiana Cutaneous Biological Research Training Program
-
批准号:8473519
-
项目类别:
-
资助金额:$13.14万
-
财政年份:2013
-
负责人:Jeffrey B. Travers
-
依托单位:
Oxidized lipids and UV immunosuppression
-
批准号:8391609
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2010
-
负责人:Jeffrey B. Travers
-
依托单位:
Oxidized lipids and UV immunosuppression
-
批准号:8762399
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2010
-
负责人:Jeffrey B. Travers
-
依托单位:
Oxidized lipids and UV immunosuppression
-
批准号:8597389
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2010
-
负责人:Jeffrey B. Travers
-
依托单位:
Oxidized lipids and UV immunosuppression
-
批准号:7932683
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2010
-
负责人:Jeffrey B. Travers
-
依托单位:
Oxidized Lipids and UV Immunosuppression
-
批准号:10293535
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2010
-
负责人:Jeffrey B. Travers
-
依托单位:
Oxidized Lipids and UV Immunosuppression
-
批准号:10514568
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2010
-
负责人:Jeffrey B. Travers
-
依托单位:
Oxidized lipids and UV immunosuppression
-
批准号:8196344
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2010
-
负责人:Jeffrey B. Travers
-
依托单位:
Bacterial Products as Potentiaters of AD
-
批准号:7150325
-
项目类别:
-
资助金额:$23.41万
-
财政年份:2006
-
负责人:Jeffrey B. Travers
-
依托单位:
PLATELET ACTIVATING FACTOR AND EPIDERMAL CYTOTOXICITY
-
批准号:6537618
-
项目类别:
-
资助金额:$30.98万
-
财政年份:1999
-
负责人:Jeffrey B. Travers
-
依托单位:
Platelet Activating Factor and Epidermal Cytoxicity
-
批准号:9883903
-
项目类别:
-
资助金额:$37.5万
-
财政年份:1999
-
负责人:Jeffrey B. Travers
-
依托单位:
Platelet Activating Factor and Epidermal Cytoxicity
-
批准号:10531858
-
项目类别:
-
资助金额:$37.5万
-
财政年份:1999
-
负责人:Jeffrey B. Travers
-
依托单位:
PLATELET ACTIVATING FACTOR AND EPIDERMAL CYTOTOXICITY
-
批准号:6184728
-
项目类别:
-
资助金额:$25.21万
-
财政年份:1999
-
负责人:Jeffrey B. Travers
-
依托单位:
海外基金